Bispecific antibody · developed by Xencor
XmAb657 is an investigational bispecific antibody that engages CD19 on B cells and CD3 on T cells. It is studied in idiopathic inflammatory myopathies, systemic sclerosis and Sjögren's disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07284797 | Phase 1 | Healthy | Recruiting | XNCR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
HealthyIdiopathic Inflammatory MyopathiesSjögren's DiseaseSystemic Sclerosis
See XNCR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
XNCR catalysts and pipeline →